5-NITRO-2-PYRIDYL-1-THIOGLUCOSIDES: APPLICATION IN SYNTHESIS OF ANALOGUES OF GLYCOSYLTRANSFERASES NATURAL SUBSTRATES by Gabriela Pastuch et al.
5-NITRO-2-PYRIDYL-1-THIOGLUCOSIDES: APPLICATION IN SYNTHESIS
OF ANALOGUES OF GLYCOSYLTRANSFERASES NATURAL SUBSTRATES
GABRIELA PASTUCH*, ROMAN KOMOR, MARTA GREC AND WIES£AW SZEJA
Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty of Chemistry,
Silesian University of Technology, Krzywoustego 4, 44-100 Gliwice, Poland
Abstract: 5-Nitro-2-pyridyl-1-thioglucosides were used in synthesis of complex uridine derivatives (13-16) in
two different sequences of reactions. In one route, the first step was glycosylation of selectively protected 5-
nitro-2-pyridyl-1-thioglucoside 1 with two different glycosyl donors (5 or 6), next, the nitro group in aglycone
of obtained disaccharides 7 or 8 was reduced and then obtained products 9 or 10 were condensed with uridine
derivatives 3 or 4 using DMT-MM as condensing agent under microwave irradiation. In the second route, con-
densation and glycosylation reactions were applied in reverse order. As it turned up, a sequence of reactions
affected the yield of final glycoconjugates 13-16 and depended on the type of uridine derivatives used. 
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Glycoconjugates play a key role in cell-cell
recognition and interaction processes. They are also
responsible for such events as inflammation, tumor
metastasis, bacterial or viral infection or activation
of immune system (1). In synthesis of glycoconju-
gates in biological systems, enzymes such as gly-
cosidases and glycosyltransferases are involved.
Glycosyltransferases of the Leloir pathway are key
enzymes responsible for synthesis of most cell-sur-
face glcoconjugates in mammalian systems. They
catalyze the transfer of a sugar moiety from an acti-
vated nucleotide sugar to the hydroxyl group of an
acceptor which may be a growing oligosaccharide, a
lipid or a protein (2). Inhibition of these enzymes
leads to the modulation of oligosaccharide biosyn-
thesis and enables recognition of their biological
functions. Therefore, some of such inhibitors might
be of therapeutic interest.
Designing of glycosyltransferases inhibitors
are generally based on analogies between the three
different moieties composing NDP sugar natural
substrates, mimicking either the carbohydrate part,
the diphosphate linkage, the nucleoside moiety or
combination of all of these. The diphosphate linkage
plays a key role in most GTs activities. It interacts
with metallic cations (e.g., Mn2+) coordinated with
two aspartate residues in an active site of enzyme (3,
4). Development of diphosphate analogues that are
capable of mimicking this interaction could provide
a new group of potent GTs inhibitors. Numerous
analogs of pyrophosphate linker have been pro-
posed, however, almost none of the proposed poten-
tial inhibitors exhibited significant activity (5ñ8).
Recently, synthesis of a new kind of sugar
nucleotides analogues, which were designed to act
as glycosyltransferases inhibitors, particularly donor
substrate analogues, was presented (9). In these gly-
coconjugates heteroaryl 1-thioglycosides deriva-
tives of D-glucose or D-galactose were connected to
selectively protected uridine by amide bond with a
succinic spacer. Studies of biological properties of
these compounds revealed that some of them exhib-
ited antiviral activity against classical swine fever
virus (CSFV) (10). 
As it turned out, the compounds reported
appeared to be quite active towards the target virus.
Thus, the following study was the synthesis of sev-
eral structural variations of already received 1-thio-
glycosyl uridine derivatives with one more sugar
unit incorporated. Synthesis of such models would
complete the already existing structures library and
biological evaluations would be enriched in infor-
mation concerning the biochemical relevance of size
and structure of sugar part of obtained glycoconju-
gates. 
EXPERIMENTAL
1H-NMR and 13C NMR spectra were recorded
for solutions in CDCl3 or DMSO-d6 with Varian
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spectrometer at 300 MHz or 600 MHz, using TMS
as the internal standard. NMR solvents were pur-
chased from ACROS Organics (Geel, Belgium).
Chemical shifts (δ) are expressed in ppm and cou-
pling constants (J) in Hz. The following abbrevia-
tions were used to explain the observed multiplici-
ties: s, singlet; d, doublet; dd, doublet of doublets;
ddd, doublet of doublet of doublets; t, triplet; dd~t,
doublet of doublets looking as triplet; m, multiplet;
b, broad. Optical rotations were measured on
PerkinñElmer 141 polarimeter using a sodium lamp
(589.3 nm) at room temperature. Mass spectra were
measured in the positive mode with a Mariner
(Perspective Biosystem) detector using the electro-
spray-ionization (ESI) technique. Microwave reac-
tions were carried out in DiscoverÆ BenchMateô
(CEM) microwave instrument, equipped with 10
mL vessels. Reactions were monitored by TLC on
aluminium sheets coated with silica gel 60 F254
(Merck). TLC plates were inspected under UV light
(λ = 254 nm) and developed by charring after spray-
ing with 10% H2SO4 in EtOH. Column chromatog-
raphy was performed on Silica Gel 60 (70ñ230
mesh, Fluka) developed with either toluene : Et3N,
toluene : AcOEt or CHCl3 : MeOH solvent systems.
Organic solvents were evaporated on a rotary evap-
orator under diminished pressure at 50OC.
5-Nitro-2-pyridyl-2,3,6-tri-O-benzoyl-1-thio-
β-D-glucopyranoside (1) (11), succinic acid mono-
2í,3í-isopropylidene-uridin-5í-yl ester (3) (9), 2í,3í-
O-isopropylideneuridine-5í-carboxylic acid (4)
(12), methyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glu-
copyranoside (5) (13) and 3,4-di-O-acetyl-2-iodo-
2,6-dideoxy-1-O-tert-butyldimethylsilyl-α-L-
mannopyranoside (6) (14) were prepared according
to the published procedures. 4-(4,6-Dimethoxy-
1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride
(DMT-MM) was synthesized according to the pro-
cedure described by Kunishima (15). Other chemi-
cals were purchased from Sigma-Aldrich, Fluka and
Acros Chemical Companies and were used without
purification. Solvents were dried and stored over
molecular sieves (4 ).
General procedures 
Procedure A: glycosylation reactions of com-
pound 5 and glycosyl acceptors 
Glycosyl acceptor 1, 11 or 12 (1 eqv.) and
methyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopy-
ranoside 5 (1.1 eqv.) were dissolved in CH2Cl2 and
then molecular sieves 4 were added. The mixture
was stirred at a room temperature for 30 min then
NIS (1.1 eqv.) and AgBF4 (0.4 eqv.) were added.
The mixture was stirred again at room temperature.
The reaction was monitored by TLC on silica gel
plates using toluene : AcOEt (1:1, v/v) solvent sys-
tem. After reaction was completed, molecular sieves
were filtered off, the reaction mixture was diluted
with CH2Cl2 and washed with brine (2◊10 mL) and
then with 1% water solution of Na2S2O3 (2◊10 mL).
The organic layer was dried over anhydrous MgSO4,
the adsorbent was filtered off and the filtrate was
concentrated to give crude product which was puri-
fied by column chromatography with toluene :
AcOEt (15:1 to 1:1, v/v) solvents system. 
Procedure B: glycosylation reactions of com-
pound 6 and glycosyl acceptors 
Glycosyl acceptor 1, 11 or 12 (1 eqv.) and 3,4-
di-O-acetyl-2-iodo-2,6-dideoxy-1-O-tert-butyl-
dimethylsilyl-α-L-mannopyranoside 6 (1.1 eqv.)
were dissolved in dry CH3CN and then molecular
sieves 4 were added. The mixture was stirred at a
room temperature for 30 min. After this time,
TMSOTf (1.1 eqv.) was added. The mixture was
stirred at 0OC and the reaction was monitored by
TLC on silica gel plates using toluene : AcOEt (1:1,
v/v) (for product 8) or CHCl3 : MeOH (10:1, v/v)
(for products 14 and 16) solvent systems. When the
reaction was completed, molecular sieves were fil-
tered off, reaction mixture was diluted with CH2Cl2
and washed with brine (2◊10 mL). The organic
layer was dried over anhydrous MgSO4, the adsor-
bent was filtered off and the filtrate was concentrat-
ed to give crude product which was purified by col-
umn chromatography. 
Procedure C: reduction of nitro group in 1-thio-
glycosides aglycone 
Compounds 1, 7 or 8 (1 eqv.) were dissolved in
CH2Cl2. To the resulting solution acetic acid and
zinc powder (8 eqv.) were added. The whole mix-
ture was stirred at room temperature. The reaction
was monitored by TLC on silica gel plates using
toluene : AcOEt (2:1, v/v) solvent system. After
completion of reaction, zinc was filtered off, the
reaction mixture was diluted with CH2Cl2 and
washed with brine (3◊10 mL). The organic layer
was dried over anhydrous MgSO4, the adsorbent
was filtered off and the filtrate was concentrated to
give crude product which was purified by column
chromatography.
Procedure D: condensation reactions of amines
with uridine derivatives 3 or 4 
To the solutions of compounds 2, 9 or 10 (1
eqv.) and uridine derivatives 3 or 4 (1 eqv.) in dry
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THF (2 mL), DMT-MM (1 eqv.) was added. The
mixtures were prepared in special tubes applied in
microwave reactor. The tube was put in the
microwave reactor and reaction was carried out at
program Standard at 50OC. The reaction was moni-
tored by TLC on silica gel plates using CH3OH :
MeOH (10:1, v/v) solvent system. After completion
of reaction, the reaction mixture was concentrated
under reduced pressure, remaining solid was dis-
solved in CH2Cl2 and washed with brine (2◊10 mL).
The organic layer was dried over anhydrous MgSO4,
the adsorbent was filtered off and the filtrate was
concentrated to give crude product which was puri-




β-D-glucopyranoside 1 (562 mg, 0.89 mmol) in
CH2Cl2 (36 mL) with addition of acetic acid (8.4
mL) and zinc powder (490 mg, 7.12 mmol) were
submitted to the general procedure C described
above. Reaction time was 30 min. Product 2 (352
mg, 66%) was obtained as a light yellow solid after
purification by column chromatography with
toluene : AcOEt (4:1 to 1:2, v/v) solvent system.
[α]20D = 55.9 (c = 0.1, CHCl3), m.p. 90ñ98OC. 1H
NMR (CDCl3, δ, ppm): 3.72 (dd, 1H, J = 5.6 Hz, J
= 12.7 Hz, H-6a), 3.80 (dd, 1H, J = 1.9 Hz, J = 12.7
Hz, H-6b), 3.94 (ddd, 1H, J = 1.9 Hz, J = 5.6 Hz, J
= 9.9 Hz, H-5), 3.82ñ4.04 (bs, 2H, NH2), 5.49 (dd~t,
1H, J = 9.8 Hz, J = 9.8 Hz, H-4), 5.56 (dd, 1H, J =
8.9 Hz, J = 10.1 Hz, H-2), 5.62 (d, 1H, J = 10.0 Hz,
H-1), 5.99 (dd~t, 1H, J = 9.1 Hz, J = 9.1 Hz, H-3),
6.85 (dd, 1H, J = 2.9 Hz, J = 8.4 Hz, H-4pyr), 7.08 (d,
1H, J = 8.4 Hz, H-3pyr), 7.11ñ7.54 (m, 9H, H-Ph),
7.78ñ7.96 (m, 6H, H-Ph), 8.05 (dd, 1H, J = 0.3 Hz,
J = 2.7 Hz, H-6pyr). 13C NMR (CDCl3, δ, ppm): 61.52
(C-6), 69.51, 70.73, 74.36, 79.22 (C-2, C-3, C-4, C-
5), 83.96 (C-1), 122.83 (C-4pyr), 126.64 (C-3pyr),
128.31, 128.35, 128.50, 128.75, 128.91, 129.71,
129.91, 133.23, 133.30, 133.59 (C-Ph), 137.88 (C-






β-D-glucopyranoside 1 (122 mg, 0.193 mmol),
methyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopy-
ranoside 5 (82 mg, 0.212 mmol), NIS (48 mg, 0.212
mmol) and AgBF4 (11 mg, 0.077 mmol) in CH2Cl2
(4 mL) were submitted to the general procedure A
described above. Reaction time: 24 h. Product 7
(105 mg, 50%) was obtained as a white solid. [α]20D
= 35.4 (c = 1.1, CHCl3), m.p. 145ñ148OC. 1H NMR
(CDCl3, δ, ppm): 1.96, 1.97, 1.98, 2.00 (4s, 12H,
CH3CO), 3.59 (ddd, 1H, J = 2.2 Hz, J = 4.8 Hz, J =
9.8 Hz, H-5íglu), 3.80 (dd, 1H, J = 6.6, Hz, J = 11.6
Hz, H-6aglu), 3.98ñ4.07 (m, 2H, H-6bglu, H-6íbglu),
4.18 (dd, 1H, J = 4.8 Hz, J = 12.3 Hz, H-6íaglu), 4.24
(ddd, 1H, J = 1.6 Hz, J = 6.6 Hz, J = 9.7 Hz, H-5glu),
4.56 (d, 1H, J = 7.8 Hz, H-1íglu), 4.90ñ5.04 (m, 3H,
H-2íglu, H-3íglu, H-4íglu), 5.51 (dd~t, 1H, J = 9.7 Hz,
J = 9.7 Hz, H-4glu), 5.71 (dd~t, 1H, J = 9.9 Hz, J =
9.9 Hz, H-2glu), 6.04 (dd~t, 1H, J = 9.4 Hz, J = 9.4
Hz, H-3glu), 6.17 (d, 1H, J = 10.3 Hz, H-1glu),
7.22ñ7.56 (m, 10H, H-Ph, H-3pyr), 7.78ñ7.96 (m,
6H, H-Ph), 8.29 (dd, 1H, J = 2.6 Hz, J = 8.8 Hz, H-
4pyr), 9.30 (d, 1H, J = 2.6 Hz, H-6pyr). 13C NMR
(CDCl3, δ, ppm): 20.53, 20.65 (CH3CO), 61.80 (C-
6íglu), 67.72 (C-6glu), 68.31, 69.22, 70.01, 70.99,
71.87, 72.62, 74.10, 78.40 (C-2glu, C-3glu, C-4glu, C-
5glu, C-2íglu, C-3íglu, C-4íglu, C-5íglu), 81.43 (C-1glu),
100.36 (C-1íglu), 122.20 (C-3pyr), 128.23, 128.39,
128.51, 128.55, 128.64, 128.70, 129.70, 129.83,
129.87 (C-Ph), 131.40 (C-4pyr), 133.33, 133.54,
133.67 (C-Ph); 142.11 (C-5pyr), 145.21 (C-6pyr),
163.66 (C-2pyr), 165.17, 165.22, 165.67, 169.13,





β-D-glucopyranoside 1 (138 mg, 0.22 mmol), 3,4-
di-O-acetyl-2-iodo-2,6-dideoxy-1-O-tert-butyl-
dimethylsilyl-α-L-mannopyranoside 6 (114 mg,
0.242 mmol) and TMSOTf (48 mL, 0.242 mmol) in
CH3CN (4 mL) were submitted to the general pro-
cedure B described above. Reaction time: 2 h.
Product 8 (134 mg, 63%) was obtained as a white
solid after purification by column chromatography
with toluene : AcOEt (30:1 to 20:1, v/v) solvent sys-
tem. [α]20D = 71.7 (c = 1.2, CHCl3), m.p. 114ñ118OC.
1H NMR (CDCl3, δ, ppm): 1.12 (d, 3H, J = 6.3 Hz,
CH3(6)man), 2.06, 2.07 (2s, 6H, CH3CO), 3.74 (dd,
1H, J = 7.2 Hz, J = 12.4 Hz, H-6aglu), 3.82 (dd, 1H,
J = 2.4 Hz, J = 12.4 Hz, H-6bglu), 3.90 (dq, 1H, J =
6.3 Hz, J = 9.5 Hz, H-5man), 4.25 (ddd, 1H, J = 2.4
Hz, J = 7.2 Hz, J = 9.8 Hz, H-5glu), 4.39 (dd, 1H, J
= 1.1 Hz, J = 4.4 Hz, H-2man), 4.46 (dd, 1H, J = 4.4
Hz, J = 9.5 Hz, H-3man), 5.06 (dd~t, 1H, J = 9.5 Hz,
J = 9.5 Hz, H-4man), 5.09 (bs, 1H, H-1man), 5.51
(dd~t, 1H, J = 9.8 Hz, J = 9.8 Hz, H-4glu), 5.72 (dd,
1H, J = 9.4 Hz, J = 10.5 Hz, H-2glu), 6.07 (dd~t, 1H,
J = 9.4 Hz, J = 9.4 Hz, H-3glu), 6.21 (d, 1H, J = 10.5
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Hz, H-1glu), 7.22ñ7.58 (m, 10H, H-Ph, H-3pyr),
7.80ñ7.99 (m, 6H, H-Ph), 8.27 (dd, 1H, J = 2.7 Hz,
J = 8.8 Hz, H-4pyr), 9.29 (dd, 1H, J = 0.8 Hz, J = 2.7
Hz, H-6pyr). 13C NMR (CDCl3, δ, ppm): 17.67 (CH3-
6man), 20.97, 21.06 (CH3CO), 30.35 (C-2man), 67.02
(C-6glu), 67.44 (C-5man), 69.15 (C-3man), 69.59, 70.06
(C-2glu, C-4glu), 72.58, 74.21 (C-3glu, C-5glu), 79.29
(C-4man), 81.43 (C-1glu), 102.29 (C-1man), 122.56 (C-
3pyr), 128.47, 128.59, 128.67, 128.75, 128.81,
128.87, 129.96, 130.10, 130.16 (C-Ph); 131.48 (C-
4pyr), 133.61, 133.81, 133.97 (C-Ph), 142.58 (C-
5pyr), 145.51 (C-6pyr), 163.87 (C-2pyr), 165.46,





Compound 7 (98 mg, 0.1 mmol) in CH2Cl2 (5
mL) with addition of acetic acid (0.5 mL) and zinc
powder (53 mg, 0.8 mmol) were submitted to the
general procedure C described above. Reaction
time: 75 min. Product 9 (58 mg, 63%) was obtained
as a light yellow solid after purification by column
chromatography with toluene : AcOEt (8:1 to 1:2,
v/v) solvent system. [α]20D = 11.2 (c = 0.4, CHCl3),
m.p. 191ñ195OC. 1H NMR (CDCl3, δ, ppm): 2.01,
2.03, 2.07 (3s, 12H, CH3CO), 3.33 (ddd, 1H, J = 2.2
Hz, J = 4.9 Hz, J = 9.5 Hz, H-5íglu), 3.70ñ4.28 (m,
7H, H-5glu, H-6aglu, H-6bglu, H-6íbglu, H-6íaglu, NH2),
4.70 (d, 1H, J = 8.1 Hz, H-1íglu), 4.89 (dd~t, 1H, J =
8.7 Hz, J = 8.7 Hz, H-2íglu), 4.98 (dd~t, 1H, J = 9.4
Hz, J = 9.4 Hz, H-4íglu), 5.06 (dd~t, 1H, J = 9.3 Hz,
J = 9.3 Hz, H-3íglu), 5.38 (dd~t, 1H, J = 9.9 Hz, J =
9.9 Hz, H-4glu), 5.60 (dd~t, 1H, J = 9.9 Hz, J = 9.9
Hz, H-2glu), 5.79 (d, 1H, J = 10.5 Hz, H-1glu), 5.97
(dd~t, 1H, J = 9.5 Hz, J = 9.5 Hz, H-3glu), 6.96 (dd,
1H, J = 2.8 Hz, J = 8.5 Hz, H-4pyr), 7.12 (d, 1H, J =
8.5 Hz, H-3pyr), 7.23ñ7.58 (m, 9H, H-Ph), 7.76ñ7.98




Compound 8 (134 mg, 0.14 mmol) in CH2Cl2
(10 mL) with addition of acetic acid (1 mL) and zinc
powder (80 mg, 0.12 mmol) were submitted to the
general procedure C described above. Reaction
time: 30 min. Product 10 (42 mg, 31%) was
obtained as a light yellow solidifying oil after purifi-
cation by column chromatography with toluene :
AcOEt (10:1 to 2:1, v/v) solvent system. [α]20D = 60.7
(c = 0.6, CHCl3). 1H NMR (CDCl3, δ, ppm): 1.08 (d,
3H, J = 6.3 Hz, CH3(6)man), 2.04, 2.08 (2s, 6H,
CH3CO), 3.60ñ3.94 (bs, 2H, NH2), 3.69 (dd, 1H, J =
6.8 Hz, J = 12.0 Hz, H-6aglu), 3.80 (dd, 1H, J = 2.0
Hz, J = 12.0 Hz, H-6bglu), 3.86 (dq, 1H, J = 6.3 Hz,
J = 9.7 Hz, H-5man), 4.11 (ddd, 1H, J = 2.0 Hz, J =
6.8 Hz, J = 9.5 Hz, H-5glu), 4.41 (dd, 1H, J = 1.0 Hz,
J = 4.5 Hz, H-2man), 4.48 (dd, 1H, J = 4.5 Hz, J = 9.5
Hz, H-3man), 5.06 (dd~t, 1H, J = 9.5 Hz, J = 9.5 Hz,
H-4man), 5.08 (bs, 1H, H-1man), 5.49 (dd~t, 1H, J =
9.8 Hz, J = 9.8 Hz, H-4glu), 5.62 (dd, 1H, J = 9.3 Hz,
J = 10.3 Hz, H-2glu), 5.80 (d, 1H, J = 10.3 Hz, H-
1glu), 5.98 (dd~t, 1H, J = 9.4 Hz, J = 9.4 Hz, H-3glu),
6.91 (dd, 1H, J = 2.9 Hz, J = 8.8 Hz, H-4pyr), 7.15 (d,
1H, J = 8.8 Hz, H-3pyr), 7.16ñ7.58 (m, 9H, H-Ph),
7.80ñ7.98 (m, 6H, H-Ph), 8.05 (d, 1H, J = 2.9 Hz,
H-6pyr). 13C NMR (CDCl3, δ, ppm): 17.63 (CH3-
6man), 21.02, 21.70 (CH3CO), 30.27 (C-2man), 67.04
(C-6glu), 67.15 (C-5man), 69.43 (C-3man), 69.91, 70.69
(C-2glu, C-4glu), 72.79, 74.59 (C-3glu, C-5glu), 78.52
(C-4man); 83.48 (C-1glu), 102.22 (C-1man), 123.47 (C-
4pyr), 125.40 (C-3pyr), 128.74, 128.97, 129.11,
129.97, 130.10, 130.20, 133.45, 133.81, 137.87 (C-
Ph), 138.11 (C-5pyr), 141.45 (C-6pyr), 142.66 (C-




thio-β-D-glucopyranoside 2 (100 mg, 0.16 mmol),
uridine derivative 3 (62 mg, 0.16 mmol) and DMT-
MM (45 mg, 0.16 mmol) in THF (2 mL) were sub-
mitted to the general procedure D described above.
Reaction time: 6 h. Product 11 (79 mg, 51%) was
obtained as a white solid after purification by col-
umn chromatography with toluene : AcOEt (10:1 to
1:2, v/v) and then CHCl3 : MeOH (80:1 to 30:1, v/v)
solvent systems. [α]20D = 64.6 (c = 0.8, CHCl3), m.p.
181ñ183OC. 1H NMR (CDCl3, δ, ppm): 1.29, 1.53
(2s, 6H, (CH3)2C), 2.58ñ2.78 (m, 4H, CH2),
3.67ñ3.87 (m, 2H, H-6aglu, H-6bglu), 4.04 (ddd, 1H, J
= 2.5 Hz, J = 5.6 Hz, J = 10.0 Hz, H-5glu), 4.31ñ4.42
(m, 3H, H-4í, H-5ía, H-5íb), 4.84 (dd, 1H, J = 3.7
Hz, J = 6.6 Hz, H-3í), 5.04 (dd, 1H, J = 1.7 Hz, J =
6.6 Hz, H-2í), 5.53 (dd~t, 1H, J = 9.8 Hz, J = 9.8 Hz,
H-4glu), 5.61 (d, 1H, J = 1.7 Hz, H-1í); 5.62ñ5.71 (m,
2H, H-5ur, H-2glu), 5.89 (d, 1H, J = 10.3 Hz, H-1glu),
6.05 (dd~t, 1H, J = 9.3 Hz, J = 9.3 Hz, H-3glu), 7.13
(d, 1H, J = 8.8 Hz, H-3pyr), 7.23ñ7.55 (m, 10H, H-Ph,
H-6ur), 7.79ñ7.98 (m, 7H, H-Ph, H-4pyr), 8.48 (d, 1H,
J = 2.2 Hz, H-6pyr), 8.78 (s, 1H, NH), 10.02 (bs, 1H,
NH). 13C NMR (CDCl3, δ, ppm): 25.73 ((CH3)3C),
25.21, 27.09 ((CH3)2C), 29.18, 29.70 (CH2), 61.53
(C-6glu), 64.15 (C-5í), 69.49, 70.44, 74.19, 79.06 (C-
2glu, C-3glu, C-4glu, C-5glu), 80.84, 82.82, 84.50, 85.38
(C-1glu, C-2í, C-3í, C-4í); 95.22 (C-1í), 102.26 (C-
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5ur), 114.44 ((CH3)2C), 124.23 (C-3pyr), 128.32,
128.39, 128.51 (C-Ph), 128.65 (C-4pyr), 128.33,
128.91, 129.71, 129.88, 129.93, 133.27, 133.39,
133.51 (C-Ph), 133.63 (C-5pyr), 140.99 (C-6pyr),
142.86 (C-6ur), 148.84 (C-2pyr), 150.19 (C-2ur),




thio-β-D-glucopyranoside 2 (152 mg, 0.246 mmol),
uridine derivative 4 (56 mg, 0.246 mmol) and DMT-
MM (70 mg, 0.32 mmol) in THF (4 mL) were sub-
mitted to the general procedure D described above.
Reaction time: 4 h. Product 12 (72 mg, 33%) was
obtained as a white solid after purification by col-
umn chromatography with toluene : AcOEt (8:1 to
1:1, v/v) solvent system. [α]20D = 117.4 (c = 0.4,
CHCl3), m.p. 171ñ175OC. 1H NMR (CDCl3, δ,
ppm): 1.35, 1.57 (2s, 6H, (CH3)2C), 3.46 (bs, 1H,
OH), 3.71 (dd, 1H, J = 6.6 Hz, J = 12.6 Hz, H-6aglu),
3.78 (dd, 1H, J = 2.0 Hz, J = 12.6 Hz, H-6bglu), 3.99
(ddd, 1H, J = 2.0 Hz, J = 6.6 Hz, J = 9.9 Hz, H-5glu),
4.71 (d, 1H, J = 2.3 Hz, H-4í), 5.24 (dd, 1H, J = 1.5
Hz, J = 6.4 Hz, H-2í), 5.31 (dd, 1H, J = 2.3 Hz, J =
6.4 Hz, H-3í), 5.48 (s, 1H, H-1í), 5.48 (dd~t, 1H, J
= 9.8 Hz, J = 9.8 Hz, H-4glu), 5.62 (dd~t, 1H, J = 9.9
Hz, J = 9.9 Hz, H-2glu), 5.69 (d, 1H, J = 7.3 Hz, H-
5ur), 5.89 (d, 1H, J = 10.3 Hz, H-1glu), 6.02 (dd~t,
1H, J = 9.4 Hz, J = 9.4 Hz, H-3glu), 7.10ñ7.58 (m,
11H, H-Ph, H-6ur, H-3pyr), 7.75ñ8.00 (m, 6H, H-Ph),
8.02 (d, 1H, J = 8.4 Hz, H-4pyr), 8.39 (d, 1H, J = 2.4
Hz, H-6pyr), 8.70 (s, 1H, NH), 9.88 (bs, 1H, NH). 13C
NMR (CDCl3), δ, ppm): 24.90, 26.86 ((CH3)2C),
61.67 (C-6glu), 69.67, 70.48, 74.20 (C-4glu, C-2glu, C-
3glu), 79.12 (C-5glu), 82.72, 82.92, 83.84, 87.85 (C-
1glu, C-2í, C-3í, C-4í), 99.61 (C-1í), 103.09 (C-5ur),
114.36 ((CH3)2C), 124.33 (C-3pyr), 128.30, 128.38,
128.52, 128.68, 128.87 (C-Ph), 128.93 (C-4pyr),
129.04, 129.71, 129.89, 129.94 (C-Ph), 132.43 (C-
5pyr), 133.23, 133.38, 133.60 (C-Ph), 141.39, 144.19
(C-6pyr, C-6ur), 149.82 (C-2pyr), 150.65 (C-2ur ),
157.98 (C-4ur), 165.31, 165.77, 165.81, 168.16
(CH3COO, PhCOO).
Glycoconjugate (13)
Route I: Compound 9 (18 mg, 0.02 mmol), uri-
dine derivative 3 (8 mg, 0.02mmol) and DMT-MM
(6 mg, 0.02 mmol) in THF (2 mL) were submitted to
the general procedure D described above. Reaction
time: 8 h. Product 13 (1 mg, 4%) was obtained after
purification by column chromatography with
toluene : AcOEt (10:1 to 1:2, v/v) and then CHCl3 :
MeOH (100:1 to 40:1, v/v) solvent systems. 
Route II: Glycoconjugate 11 (40 mg, 0.042 mmol),
methyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopy-
ranoside 5 (19 mg, 0.046 mmol), NIS (10 mg, 0.046
mmol) and AgBF4 (0.3 mg, 0.002 mmol) in CH2Cl2
(2 mL) were submitted to the general procedure A
described above. Reaction time: 1 hour. Product 13
(18 mg, 32%) was obtained as a white solid after
purification by column chromatography with
toluene : AcOEt (10:1 to 1:2, v/v) and then CHCl3 :
MeOH (100:1 to 40:1, v/v) solvents systems. 
[α]20D = 43.5 (c = 0.3, CHCl3), m.p. 129ñ131OC. ESI-
MS: calcd. for C62H64N4O25SNa ([M + Na]+): m/z
1319.35; found: m/z 1319.5. 1H NMR (CDCl3, δ,
ppm): 1.31, 1.55 (2s, 6H, (CH3)2C), 1.95, 2.03, 2.07,
2.08 (4s, 12H, CH3CO), 2.60ñ2.79 (m, 4H, CH2);
3.80 (d, 1H, J = 12.8 Hz, H-6aglu), 4.02 (dd, 1H, J =
7.6 Hz, J = 12.8 Hz, H-6bglu), 4.03 (dd, 1H, J = 1.8
Hz, J = 12.2 Hz, H-6íaglu), 4.10 (dd, 1H, J = 4.8 Hz,
J = 12.2 Hz, H-6íbglu), 4.17 (dd, 1H, J = 7.6 Hz, J =
9.9 Hz, H-5glu), 4.22ñ4.42 (m, 4H, H-4í, H-5ía, H-
5íb, H-5íglu), 4.78 (d, 1H, J = 7.3 Hz, H-1íglu), 4.82
(dd, 1H, J = 3.7 Hz, J = 6.3 Hz, H-3í), 4.84ñ4.97 (m,
3H, H-2íglu, H-3íglu, H-4íglu), 5.01 (dd, 1H, J = 1.8
Hz, J = 6.3 Hz, H-2í), 5.38 (dd~t, 1H, J = 9.9 Hz, J
= 9.9 Hz, H-4glu), 5.59ñ5.65 (m, 2H, H-2glu, H-1í),
5.72 (d, 1H, J = 8.1 Hz, H-5ur), 6.02 (dd~t, 1H, J =
9.4 Hz, J = 9.4 Hz, H-3glu), 6.04 (d, 1H, J = 10.4 Hz,
H-1glu), 7.19 (d, 1H, J = 8.7 Hz, H-3pyr), 7.22ñ7.56
(m, 10H, H-Ph, H-6ur), 7.77ñ7.98 (m, 6H, H-Ph),
8.12 (dd, 1H, J = 2.4 Hz, J = 8.7 Hz, H-4pyr), 8.32 (s,
1H, NH), 8.53 (d, 1H, J = 2.4 Hz, H-6pyr), 8.82 (bs,
1H, NH). 13C NMR (CDCl3, δ, ppm): 20.48, 20.75,
20.78, 20.84 (CH3CO), 25.23, 27.12 ((CH3)2C),
28.91, 31.37 (CH2), 61.62 (C-6íglu), 64.10, 66.35,
68.12, 69.26, 69.91, 71.49, 71.63, 73.30, 74.11 (C-
6glu, C-5í, C-5íglu, C-2glu, C-3glu, C-4glu, C-2íglu, C-
3íglu, C-4íglu), 79.79, 80.89, 81.76, 84.49, 85.24 (C-
1glu, C-5glu, C-2í, C-3í, C-4í); 94.99 (C-1í); 98.51
(C-1íglu), 102.55 (C-5ur), 123.32 (C-3pir), 128.30,
128.38, 128.48, 128.65, 128.75, 128.90 (C-Ph),
129.12 (C-4pyr), 129.69, 129.86, 129.91, 132.96,
133.28, 133.41 (C-Ph), 133.60 (C-5pyr), 141.58,
142.31 (C-6pyr, C-6ur), 149.82, 149.96 (C-2ur, C-2pyr),
162.89 (C-4ur), 165.30, 165.43, 165.76, 169.38,
169.56, 170.14, 170.69, 171.44, 172.27 (CH3COO,
PhCOO).
Glycoconjugate (14)
Route I: Compound 10 (21 mg, 0.022 mmol),
uridine derivative 3 (9 mg, 0.022 mmol) and DMT-
MM (6 mg, 0.022 mmol) in THF (2 mL) were sub-
mitted to the general procedure D described above.
Reaction time: 6 h. Product 14 (2 mg, 6%) was
obtained after purification by column chromatogra-
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phy with toluene : AcOEt (10:1 to 1:2, v/v) and then
CHCl3 : MeOH (100:1 to 60:1, v/v) solvent systems. 
Route II: Glycoconjugate 11 (39 mg, 0.041 mmol),
3,4-di-O-acetyl-2-iodo-2,6-dideoxy-1-O-tert-butyl-
dimethylsilyl-α-L-mannopyranoside 6 (22 mg,
0.045 mmol), TMSOTf (9 mL, 0.045 mmol) in
CH3CN (2 mL) were submitted to the general pro-
cedure B described above. Reaction time: 10 min.
Product 14 (16 mg, 29%) was obtained as a white
solid after purification by column chromatography
with toluene : AcOEt (10:1 to 1:2, v/v) and then
CHCl3 : MeOH (100:1 to 60:1, v/v) solvent systems.
[α]20D = 46.2 (c = 0.4, CHCl3), m.p. 138ñ142OC. ESI-
MS: calcd. for C59H63IN4O21SNa ([M + Na]+): m/z
1345.26; found: m/z 1329.4. 1H NMR (CDCl3, δ,
ppm): 1.03 (d, 3H, J = 6.3 Hz, CH3(6)man), 1.31, 1.55
(2s, 6H, (CH3)2C), 2.07, 2.12 (2s, 6H, CH3CO),
2.61ñ2.82 (m, 4H, CH2), 3.66 (dd, 1H, J = 7.6 Hz, J
= 12.0 Hz, H-6aglu), 3.78 (dd, 1H, J = 1.5 Hz, J =
12.0 Hz, H-6bglu), 3.85 (dq, 1H, J = 6.3 Hz, J = 9.7
Hz, H-5man), 4.19 (ddd, 1H, J = 1.7 Hz, J = 7.6 Hz,
J = 9.3 Hz, H-5glu), 4.29ñ4.41 (m, 3H, H-4í, H-5ía,
H-5íb), 4.43 (dd, 1H, J = 0.7 Hz, J = 4.6 Hz, H-
2man), 4.49 (dd, 1H, J = 4.6 Hz, J = 9.3 Hz, H-3man),
4.82 (dd, 1H, J = 3.7 Hz, J = 6.6 Hz, H-3í), 5.01 (dd,
1H, J = 1.9 Hz, J = 6.6 Hz, H-2í), 5.06 (bs, 1H, H-
1man), 5.07 (dd~t, 1H, J = 9.7 Hz, J = 9.7 Hz, H-
4man), 5.48 (dd~t, 1H, J = 9.9 Hz, J = 9.9 Hz, H-4glu),
5.63 (d, 1H, J = 1.9 Hz, H-1í), 5.68 (dd, 1H, J = 9.3
Hz, J = 10.5 Hz, H-2glu), 5.72 (dd, 1H, J = 1.5 Hz, J
= 7.6 Hz, H-5ur), 6.03 (d, 1H, J = 10.5 Hz, H-1glu),
6.04 (dd~t, 1H, J = 9.4 Hz, J = 9.4 Hz, H-3glu), 7.14
(d, 1H, J = 8.6 Hz, H-3pyr), 7.22ñ7.58 (m, 10H, H-
Ph, H-6ur), 7.79ñ7.98 (m, 6H, H-Ph), 8.08 (dd, 1H, J
= 2.4 Hz, J = 8.6 Hz, H-4pyr), 8.28 (s, 1H, NH), 8.45
(d, 1H, J = 2.4 Hz, H-6pyr); 8.91 (bs, 1H, NH). 13C
NMR (CDCl3, δ, ppm): 17.28 (CH3-6man), 20.80,
21.35 (CH3CO), 25.25, 27.15 ((CH3)2C), 29.13,
29.47 (CH2), 31.66 (C-2man), 64.20 (C-5í), 66.67,
66.80 (C-6glu, C-5man), 69.69 (C-3man), 70.25 (C-4glu),
72.41, 74.36 (C-2glu, C-4man), 77.38, 78.48 (C-3glu,C-
5glu), 80.89, 82.02, 84.46, 85.23 (C-1glu, C-2í, C-3í,
C-4í), 94.95 (C-1í), 101.76 (C-1man), 102.58 (C-5ur),
114.64 ((CH3)2C), 123.29 (C-3pyr), 128.33, 128.38,
128.53, 128.71, 128.83, 128.97, 129.75, 129.84,
129.93 (C-Ph, C-4pyr), 132.71 (C-5pyr), 133.28,
133.37, 133.62 (C-Ph), 141.15 (C-6pyr), 142.33 (C-
6ur), 149.52 (C-2pyr), 149.84 (C-2ur), 162.94 (C-4ur),
165.32, 165.80, 169.76, 169.86, 170.75, 172.38
(CH3COO, PhCOO).
Glycoconjugate (15)
Route I: Compound 9 (40 mg, 0.044 mmol), uri-
dine derivative 4 (13 mg, 0.044 mmol) and DMT-MM
(12 mg, 0.044 mmol) in THF (2 mL) were submitted
to the general procedure D described above. Reaction
time: 9 h. Product 15 (23 mg, 43%) was obtained after
purification by column chromatography with toluene :
AcOEt (10:1 to 1:2, v/v) solvents system. 
Route II: Glycoconjugate 12 (36 mg, 0.041
mmol), methyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-
glucopyranoside 5 (19 mg, 0.045 mmol), NIS (10
mg, 0.045 mmol) and AgBF4 (0.3 mg, 0.002 mmol)
in CH2Cl2 (2 mL) were submitted to the general pro-
cedure A described above. Reaction time: 3 h.
Product 13 (3 mg, 7%) was obtained as a white solid
after purification by column chromatography with
toluene : AcOEt (10:1 to 1:2, v/v) and then toluene :
AcOEt (4:1 to 3:1, v/v) solvent systems. [α]20D = 23 (c
= 0.8, CHCl3), m.p. 130ñ134OC. ESI-MS: calcd. for
C58H58N4O23SNa ([M + Na]+): m/z 1233.31; found:
m/z 1233.5. 1H NMR (CDCl3, δ, ppm): 1.37, 1.59
(2s, 6H, (CH3)2C), 1.91, 1.97, 1.98, 2.01 (4s, 12H,
CH3CO), 3.54 (ddd, 1H, J = 2.2 Hz, J = 4.9 Hz, J =
9.1 Hz, H-5glu), 3.81 (dd, 1H, J = 7.3 Hz, J = 11.7
Hz, H-6aglu), 3.96 (dd, 1H, J = 1.3 Hz, J = 10.7 Hz,
H-6bglu), 4.03 (dd, 1H, J = 2.2 Hz, J = 12.1 Hz, H-
6íaglu), 4.18 (dd, 1H, J = 5.0 Hz, J = 12.0 Hz, H-
6íbglu), 4.19 (m, 1H, H-5glu), 4.59 (d, 1H, J = 7.2 Hz,
H-1íglu), 4.74 (d, 1H, J = 2.3 Hz, H-4í), 4.98ñ5.06
(m, 3H, H-2íglu, H-3íglu, H-4íglu), 5.24 (dd, 1H, J =
1.8 Hz, J = 6.3 Hz, H-2í), 5.32 (dd, 1H, J = 2.3 Hz,
J = 6.3 Hz, H-3í), 5.43 (dd~t, 1H, J = 9.8 Hz, J = 9.8
Hz, H-4glu), 5.52 (d, 1H, J = 1.8 Hz, H-1í),
5.59ñ5.65 (dd~t, 1H, J = 9.9 Hz, J = 9.9 Hz, H-2glu),
5.77 (d, 1H, J = 7.9 Hz, H-5ur), 5.97 (d, 1H, J = 10.6
Hz, H-1glu), 5.98 (dd~t, 1H, J = 9.5 Hz, J = 9.5 Hz,
H-3glu), 7.13ñ7.55 (m, 11H, H-Ph, H-3pyr, H-6ur),
7.76ñ7.96 (m, 6H, H-Ph), 8.01 (dd, 1H, J = 2.5 Hz, J
= 8.6 Hz, H-4pyr), 8.48 (d, 1H, J = 2.5 Hz, H-6pyr),
8.60 (s, 1H, NH), 9.55 (bs, 1H, NH). 13C NMR
(CDCl3, δ, ppm): 20.47, 20.57, 20.66 (CH3CO),
24.94, 26.87 ((CH3)2C), 61.89 (C-6íglu), 68.09, 68.42,
69.44, 70.16, 71.13, 71.76, 72.94, 74.26 (C-6 glu, C-
2glu, C-4glu, C-4glu, C-2íglu,C-3íglu, C-4íglu, C-5íglu),
78.17, 82.47, 83.06, 83.80, 87.85 (C-2í, C-3í, C-4í,
C-5glu, C-1glu), 99.37 (C-1í), 100.20 (C-1íglu), 103.24
(C-5ur), 114.39 (C(CH3)2), 123.44 (C-3pyr), 128.23,
128.30, 128.35, 128.50, 128.69, 128.80, 128.96,
129.69, 129.83, 129.88 (C-Ph, C-4pyr), 132.27 (C-
5pyr), 133.25, 133.36, 133.60 (C-Ph), 141.51, 143.74
(C-6ur, C-6pyr), 150.27, 150.68 (C-2ur, C-2pyr), 162.69
(C-4ur), 165.28, 165.35, 165.74, 167.92, 169.51,
170.17, 170.50, 170.76 (CH3COO, PhCOO).
Glycoconjugate (16)
Route I: Compound 10 (21 mg, 0.022 mmol), uri-
dine derivative 4 (7 mg, 0.022 mmol) and DMT-MM
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(6 mg, 0.022 mmol) in THF (2 mL) were submitted to
the general procedure D described above. Reaction
time: 6 h. Product 16 (6 mg, 22%) was obtained after
purification by column chromatography with toluene :
AcOEt (10:1 to 1:2, v/v) solvents system. 
Route II: Glycoconjugate 12 (36 mg, 0.041
mmol), 3,4-di-O-acetyl-2-iodo-2,6-dideoxy-1-O-
tert-butyldimethylsilyl-α-L-mannopyranoside 6 (22
mg, 0.045 mmol), TMSOTf (9 µL, 0.045 mmol) in
CH3CN (2 mL) were submitted to the general pro-
cedure B described above. Reaction time: 15 min.
Product 16 (38 mg, 75%) was obtained as a white
solid after purification by column chromatography
with toluene : AcOEt (10:1 to 1:2, v/v) solvent sys-
tem. [α]20D = 21.2 (c = 0.34, CHCl3), m.p. 135-139OC.
ESI-MS: calcd. for C54H53IN4O19SNa ([M + Na]+):
m/z 1243.20; found: m/z 1243.3. 1H NMR (CDCl3, δ,
ppm): 1.05 (d, 3H, J = 6.3 Hz, CH3(6)man), 1.36, 1.56
Figure 1. Substrates for glycoconjugates synthesis
Scheme 1. Synthesis of disaccharides derivatives of 5-amino-2-pyridyl-1-thioglucoside
5-Nitro-2-pyridyl-1-thioglucosides: application in synthesis of analogues... 649
(2s, 6H, (CH3)2C), 2.04, 2.08 (2s, 6H, CH3CO), 3.73
(dd, 1H, J = 6.9 Hz, J = 12.2 Hz, H-6aglu), 3.78 (dd,
1H, J = 1.7 Hz, J = 12.2 Hz, H-6bglu), 3.83 (dq, 1H,
J = 6.3 Hz, J = 9.7 Hz, H-5man), 4.21 (ddd, 1H, J =
1.7 Hz, J = 6.9 Hz, J = 9.4 Hz, H-5glu), 4.49 (d, 1H,
J = 4.6 Hz, H-2man), 4.52 (dd, 1H, J = 4.6 Hz, J = 9.3
Hz, H-3man); 4.70 (d, 1H, J = 2.5 Hz, H-4í); 5.05
(dd~t, 1H, J = 9.5 Hz, J = 9.5 Hz, H-4man), 5.13 (s,
1H, H-1man), 5.23 (dd, 1H, J = 2.1 Hz, J = 6.3 Hz, H-
2í), 5.25 (dd, 1H, J = 2.5 Hz, J = 6.3 Hz, H-2í), 5.47
(d, 1H, J = 2.1 Hz, H-1í), 5.50 (dd~t, 1H, J = 9.8 Hz,
J = 9.8 Hz, H-4glu), 5.66 (dd~t, 1H, J = 9.9 Hz, J =
9.9 Hz, H-2glu), 5.77 (d, 1H, J = 7.9 Hz, H-5ur), 5.97
(d, 1H, J = 10.4 Hz, H-1glu), 6.01 (dd~t, 1H, J = 9.5
Hz, J = 9.5 Hz, H-3glu), 7.12ñ7.56 (m, 11H, H-Ph, H-
3pyr, H-6ur), 7.79ñ7.98 (m, 6H, H-Ph), 8.04 (dd, 1H, J
= 2.5 Hz, J = 8.7 Hz, H-4pyr), 8.44 (d, 1H, J = 2.5 Hz,
H-6pyr), 8.73 (s, 1H, NH), 9.65 (bs, 1H, NH). 13C
NMR (CDCl3, δ, ppm): 17.34 (CH3-6man), 20.79,
21.04 (CH3CO), 25.02, 27.00 ((CH3)2C), 29.71 
(C-2man), 66.33 (C-6glu), 66.92 (C-5man), 69.42 (C-
3man), 69.58 (C-4glu), 70.14 (C-2glu), 72.49 (C-4man),
74.29 (C-3glu), 78.56 (C-5glu), 82.33 (C-1glu), 82.64,
83.60 (C-2í, C-3í), 87.37 (C-4í), 99.44 (C-1í),
101.62 (C-1man), 103.34 (C-5ur), 114.75 ((CH3)2C),
123.38 (C-3pyr), 128.31, 128.36, 128.39, 128.53,
128.69, 128.82, 128.99, 129.74, 129.87, 129.91 (C-
Ph, C-4pyr), 132.26 (C-5pyr), 133.25, 133.36, 133.60
(C-Ph); 141.33 (C-6pyr); 143.77 (C-6ur), 150.24 (C-
2ur), 150.72 (C-2pyr), 162.63 (C-4ur), 165.29, 165.77,
167.64, 169.84, 170.89 (CH3COO, PhCOO).
RESULTS AND DISCUSSION
Taking into consideration earlier reported
structure of potential GTs inhibitors as well as
abovementioned structural requirements for ana-
logues of GTs natural substrates, new group of gly-
coconjugates with one more sugar unit added to ear-
lier obtained 1-thioglucosyl uridine derivatives were
Scheme 2. Synthesis of selectively protected glycoconjugates 11 and 12
Scheme 3. Two different routes for synthesis of glycoconjugates 13-16
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synthesized. As an additional sugar unit derivatives
of glucose or 2-iodo-2-deoxy mannose were chosen
(Fig. 1).
Extension of sugar part of glycoconjugates
could be obtained in two different procedures. One
of them would be glycosylation using selectively
protected 5-nitro-2-pyridyl-1-thioglucoside 1 as
acceptor and donors 5 or 6. Next, the nitro group in
aglycone of obtained disaccharides 7 or 8 could be
reduced (Scheme 1) and finally reduced products 9
or 10 could be used in condensation reaction with
uridine derivatives 3 or 4. Second way would be gly-
cosylation reaction of previously obtained selective-
ly protected glycoconjugates 11 or 12 (Scheme 2)
used as glycosyl acceptors with compounds 5 or 6 as
glycosyl donors (Scheme 3). 
For synthesis of disaccharides 7 or 8 selective-
ly protected 5-nitro-2-pyridyl-1 thioglucoside 1 was
selected as glycosyl acceptor. Simple and efficient
synthesis of this compound was described a few
years ago [11]. Glycosylation conditions were
adjusted to type of used glycosyl donor. So, for gly-
cosylation with methyl-1-thioglucoside 5 as glyco-
syl donor NIS/AgBF4 system was applied as a pro-
moter. According to the recently reported data, 1-
thioglycosides could be activated by this system and
coupling reactions proceeded very rapidly and pro-
vided the corresponding disaccharide in minutes
(16). For activation of 3,4-di-O-acetyl-2-iodo-2,6-
dideoxy-1-O-tert-butyldimethylsilyl-α-L-mannopy-
ranoside 6 TMSOTf was marked out and glycosyla-
tion was performed in CH3CN as a solvent (14).
Application of such reaction conditions allowed to
obtain expected disaccharides 7 and 8 in proper
yields 50% and 63%, respectively. For reduction of
a nitro group in aglycone of these two disaccharides,
reduction procedure with zinc powder/acetic acid
system in CH2Cl2, previously described by Roy and
co-workers for 4-nitrophenyl-1-thioglycosides (17)
and recently utilized for other derivatives of 5-nitro-
2-pyridyl-1-thioglycosides (9), was applied. React-
ion proceeded at room temperature and 5-amino-2-
pyridyl-1-thioglycosides 9 and 10 were obtained
with 63% and 31% yield, respectively. Both
obtained compounds were used for condensation
reactions with uridine derivatives 3 and 4. Amide
bond formation in reaction between amine and car-
boxylic acid becomes feasible at high temperature or
in the presence of a wide range of condensing agents
(18). Kaminski and co-workers showed the efficien-
cy of 2-chloro-4,6-disubstituted-1,3,5-triazines in
the presence of tertiary amine (e.g., N-methylmor-
pholine) in formation of the peptide bond. So-called
ìsuperactive esterî containing an excellent leaving
group was formed in this reaction (19). Kunishima
and co-workers found that 4-(4,6-dimethoxy-1,3,5-
Table 1. Reactions conditions and yields of the synthesized compounds.
Entry Substrate I Substrate II Reaction conditions Product 
Yield
[%]
1. 1 - Zn, AcOH, CH2Cl2, 30 min. 2 66
2. 1 5 NIS/AgBF4, CH2Cl2, MS 4, 24 h 7 50
3. 1 6 TMSOTf, CH3CN, MS 4, 2 h 8 63
4. 7 - Zn, AcOH, CH2Cl2, 75 min. 9 63
5. 8 - Zn, AcOH, CH2Cl2, 30 min. 10 31
6. 2 3 THF, DMT-MM, 50OC, MW, 6 h 11 51
7. 2 4 THF, DMT-MM, 50OC, MW, 4 h 12 33
8. 9 3 THF, DMT-MM, 50OC, MW, 8 h 13 4
9. 10 3 THF, DMT-MM, 50OC, MW, 6 h 14 6
10. 9 4 THF, DMT-MM, 50OC, MW, 9 h 15 43
11. 10 4 THF, DMT-MM, 50OC, MW, 6 h 16 22
12. 11 5 NIS/AgBF4, CH2Cl2, MS 4, 1 h 13 32
13. 11 6 TMSOTf, CH3CN, MS 4, 10 min. 14 29
14. 12 5 NIS/AgBF4, CH2Cl2, MS 4, 3 h 15 7
15. 12 6 TMSOTf, CH3CN, MS 4, 15 min. 16 75 
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triazin-2-yl)-4-methyl-morpholinium chloride
(DMT-MM) can be formed and isolated in THF and
then used as an efficient condensing agent facilitat-
ing formation of amides and esters (20). Successful
application of DMT-MM as condensing agent for
preparation of glycoconjugates derivatives of uri-
dine 3 was described last year (9). The only draw-
back of this method was a long reaction time, even
two days. In order to avoid such long reaction time
in amide bond formation, microwave irradiation
could be applied (21, 22). For condensation of
amine group in aglycone of disaccharides 9 and 10
with carboxylic group in uridine derivatives 3 and 4,
DMT-MM was applied as condensing agent in com-
bination with microwave irradiation (Standard pro-
gram, 50OC). As a result of these reactions, glyco-
conjugates 13-16 were obtained. Yields of these
products are presented in Table 1. 
In the second procedure, glycoconjugates 11
and 12 were obtained first with application of the
same condensation conditions as described above.
Then, these compounds were used in glycosylation
reactions with glycosyl donors 5 or 6. Also in this
case, the expected glycoconjugates 13-16 were
obtained. As it turned out, both reactions sequences
led to the expected products. It is worth mentioning
that final condensation of disaccharides 9 or 10 with
uridine derivative 3 allow to obtain glycoconjugates
13 and 14 with rather poor yield of 4% and 6%,
respectively). The same route in the case of uridine
derivatives 4 supplied glycoconjugates 15 and 16
with considerably better yields. 
All products were purified by column chro-
matography and their structure was determined by
1H and 13C NMR spectroscopy. Final uridine deriva-
tives of 1-thioglycosides 13-16 were additionally
characterized on the basis of mass spectrometry.
The obtained spectra proved the structure of glyco-
conjugates 13-16. New singlet of amide proton ori-
gin appeared in 1H NMR spectra of obtained glyco-
conjugates, whereas a broad signal from two amine
protons present in spectra of the substrates used dis-
appeared in the productís spectra. 
Biological activity of glycoconjugates 13-16
will be tested, paying special attention to a possible
inhibition of enzymes from glycosyltransferases
group, especially 1,4-β-galactosyltransferase.
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